



San Antonio Breast Cancer Symposium

The American Hospital of Paris and Predilife have presented the results of a breast cancer risk assessment using MammoRisk

Paris, 17 December 2020, 17h30 CET: Predilife (FR0010169920, ALPRE) – a company developing innovative solutions predicting the risk of diseases to facilitate personalised medicine – and the American Hospital of Paris have revealed at the San Antonio Breast Cancer Symposium the results of a study obtained from a cohort of 175 patients who underwent a breast cancer risk assessment at the Women's Risk Institute of the American Hospital of Paris using MammoRisk, the test predicting breast cancer risk for women aged 40 or older.

Out of 175 patients aged 39 to 70:

- 25% were revealed to have a higher than average risk of developing breast cancer, warranting more intensive screening (an annual mammogram instead of once every two years as currently recommended)
- Among them, 27% are aged 40 to 49, an age group for which there are no current screening recommendations.

*Breast cancer risk assessment combined with a polygenic risk score in the general population for personalized screening M. SAGHATCHIAN¹, M. ABEHSERA¹, R. SIGAL¹, E. GAUTHIER², V. HELIN², L. VILLOING-GAUDE³, C. REYES³, A. RAPINAT³, D. GENTIEN³, L. GOLMARD⁴, D. STOPPA-LYONNET⁴
¹American Hospital of Paris, Neuilly-sur-Seine, FRANCE, ²Predilife, Villejuif, FRANCE, ³Institut Curie, Paris, FRANCE, ⁴Institut Curie Hospital/Paris Descartes Sorbonne-Paris-Cité University/INSERM U830, D.R.U.M. team, Paris, FRANCE*



For study leader and medical oncologist Professor Mahasti Saghatchian, head of the American Hospital of Paris Breast Centre and Women's Risk Institute, and member of the Gustave Roussy Breast Disease Committee: *'Organised screening makes it possible to detect cancers earlier and save lives. But it can also miss more serious interval cancers that develop between mammograms or cancers occurring before the age of 50. The role of the polygenic risk score (PRS), combined with the analysis of breast density and other major risk factors is important for the early detection of tumours. We observe that around half of women are reclassified once the PRS score is obtained, and with a fairly uniform distribution: 50% of the at-risk patients move into a lower risk category and 50% into a higher risk category. It is important for doctors to have this information as early as possible, to establish personalised monitoring for patients from the age of 40.'*



About MammoRisk®

MammoRisk® enables doctors to offer each of their female patients, from the age of 40, the possibility to assess their risk of developing breast cancer over the next 5 years and to establish a personalised monitoring programme. The test is based on three pillars: **the patient's clinical data** (age, family history, breast biopsy), **breast density** – evaluated using mammograms, and **polygenic risk score** – produced by analysing polymorphisms associated with breast cancer risk (from a saliva sample). MammoRisk® is a simple and rapid addition to the standard mammogram screening protocol.

About the American Hospital of Paris and the Women's Risk Institute - www.american-hospital.org

Founded in 1906, the American Hospital of Paris is a private, not-for-profit healthcare institution of recognised public benefit, whose mission is to deliver the best in French and American medical practices to its French and international patients. The American Hospital of Paris offers global expertise, bringing together in a single location the most innovative investigative technologies, the latest therapeutic advances and tailored medical care, enabling patients to benefit from personalised care within very short time frames. The American Hospital of Paris is accredited by both the French National Authority for Health and the American Joint Commission according to the standards applied in the United States. The American Hospital of Paris is France's top-ranking healthcare institution in terms of patient satisfaction ahead of all other public or private facilities providing medical, surgical and obstetric services*. The American Hospital of Paris offers an innovative approach to women aged 40 or older with no history of breast cancer: the Women's Risk Institute programme to evaluate the individual risk of breast cancer and offer a personalised prevention and monitoring programme. The principal objective of the Women's Risk Institute is to evaluate each woman's personal risk of developing breast cancer, and propose a personalised screening strategy and a prevention programme to correct the risk factors to which she is exposed.

(*2017 and 2018 data for all patients hospitalised for more than 48 hours at the American Hospital of Paris and who answered a questionnaire administered by the French National Authority for Health).

About Predilife - www.predilife.com

Predilife (Euronext Growth Paris: ALPRE), has pioneered the design and development of forecasting tests giving everyone the chance to find out their own risk of contracting serious diseases. It combines proven medical techniques (genetic tests, medical imaging, etc.) with mathematical models underpinned by statistical data. Predilife markets **MammoRisk®**, a breast cancer risk predictive test, and DenSeeMammo, a software solution for measuring breast density, in Europe and in the United States.



PREDILIFE
prédire pour prévenir



Predilife is handling the assessment of breast cancer risk in the leading MyPeBS European study promoted by Unicancer and funded by the European Union. The study's main goal is to compare the efficacy of the existing organised screening framework based on the criterion of age alone with a new screening strategy based on each woman's level of risk (Horizon 2020 research and innovation programme under grant agreement no. 755394).

LinkedIn Predilife: <https://www.linkedin.com/company/predilife/>

Predilife media contact:

Annie-Florence Loyer - afloyer@newcap.fr –
+ 33 (0) 1 44 71 00 12 / + 33 (0) 6 88 20 35 59

AHP contact:

Samantha Leblanc - Director of Communications samantha.leblanc@ahparis.org
+ 33 (0)1 46 41 83 33